The clinical and physiological spectrum of interferon‐alpha induced thyroiditis: Toward a new classification
Jamie C. Mandac, Sonal Chaudhry, Kenneth E. Sherman, Yaron Tomer – 23 March 2006 – Interferon‐alpha (IFNα) is a major treatment modality for several malignant and nonmalignant diseases, especially hepatitis C. Prospective studies have shown that up to 15% of patients with hepatitis C receiving IFNα develop clinical thyroid disease, and up to 40% were reported to develop thyroid antibodies. Some of these complications may result in discontinuation of interferon therapy. Thus, interferon induced thyroiditis (IIT) is a major clinical problem for patients receiving interferon therapy.